Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. ConvaTec Group Plc
  6. News
  7. Summary
    CTEC   GB00BD3VFW73

CONVATEC GROUP PLC

(CTEC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ConvaTec : Annual Results for the twelve months ended 31 December 2020 05 March 2021

03/05/2021 | 02:05am EDT

05 March 2021

Download press release

Solid growth and good strategic progress

FY 2020 key highlights:

  • Improved revenue growth: +3.7% reported growth and +4.0% on a constant currency2
  • Attractive diversified portfolio providing resilience during the pandemic.
    • FY20 performance driven by strong growth in Infusion Care and Continence & Critical Care offsetting limited growth in Ostomy Care and decline in Advanced Wound Care.
    • Q4 revenue performance reflected the impact of the latest COVID-19 resurgence late in the year. This was driven primarily by better than expected revenues in Continence & Critical Care.
  • Continued investment for growth: Adjusted1 EBIT margin of 18.5% (2019: 19.4%) in line with the latest guidance.
  • Strong adjusted free cash flow1: $347 million (2019: $397 million) and adjusted cash conversion1 of 90% (2019: 98%).
  • Strengthened balance sheet: Reduction in leverage to 2.0x Net Debt/Adjusted EBITDA1 (2019: 2.5x).
  • Proposed dividend of 3.983 cents to take FY dividend to 5.7 cents, in line with prior year.

Good operational and strategic progress as we pivot to sustainable and profitable growth:

  • Effective response to COVID-19 - safeguarding the health and wellbeing of our people, addressing customer needs and strengthening our supply chain.
  • Further positive operational progress - adjusted gross margin1 increased from 59.0% to 59.5% or $1,127 million.
  • Continued to make good progress with our FISBE (Focus, Innovate, Simplify, Build, Execute) strategy. Achievements in the year include:
    • Strengthening the leadership team; embedding the new operating model; increasing investment in R&D to 4.3% of revenue (2019: 2.9%); establishing Centres of Excellence; setting up a Global Business Services centre and disposal of the US Skincare product line.
  • Certain transformation initiatives were proactively re-phased given the COVID-19 backdrop - we spent $93 million on strategic operational investments in 2020. We remain on track to deliver $130-$150 million of gross benefits in 2021.
  • Positive outlook: We expect to see 2021 organic4 revenue growth of between 3-4.5% and a constant currency adjusted EBIT margin of 18-19.5%.

Karim Bitar, Chief Executive Officer, commented:

'I am pleased with our strategic progress and how the business performed in 2020. Against the backdrop of COVID-19 we set our new strategic direction of travel, responded well to the needs of our customers and improved our operational performance. In addition our ongoing strategic transformation remains firmly on track.

'The outlook for 2021 is positive although uncertainty surrounding COVID-19 persists. We expect to see 2021 organic4 revenue growth of between 3-4.5% and a constant currency adjusted EBIT margin of 18-19.5% as we continue to invest in our transformation, some of which was deferred from 2020, and as COVID-suppressed costs begin to normalise.

'There is still further work ahead for the Group as we continue to strengthen our foundations and begin to pivot to sustainable and profitable growth, but I am confident in the inherent attractiveness of the markets we serve and in ConvaTec's growth prospects.'

Group revenue

For insight into the category performances see pages 5 to 7.

(...)

Download the full text of this announcement

Analysts and Investors

ir@convatec.com

Kate Postans: Vice President of Investor Relations & Corporate Communications

+44 (0)7826 447807

Media

Buchanan: Charles Ryland / Chris Lane

+44 (0)207 466 5000

Disclaimer

ConvaTec Group plc published this content on 05 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 March 2021 07:04:01 UTC.


© Publicnow 2021
All news about CONVATEC GROUP PLC
03/31CONVATEC  : awarded contract for Ostomy Products from Vizient, Inc. 31 March 202..
PU
03/05CONVATEC  : Maintains Dividend in 2020 as Profit Skyrockets
MT
03/05CONVATEC  : Annual Results for the twelve months ended 31 December 2020 05 March..
PU
03/05CONVATEC  : Earnings Flash (CTEC.L) CONVATEC GROUP Posts FY20 EPS $0.0560
MT
03/05CONVATEC  : Earnings Flash (CTEC.L) CONVATEC GROUP Posts FY20 Revenue $1.89B
MT
02/24PRESS RELEASE  : Creative Balloons closes EUR15 million growth financing and app..
DJ
01/04CONVATEC  : JPMorgan Raises Convatec To Neutral From Underweight, Ups PT
MT
2020CONVATEC  : Moody's Affirms Convatec's Ratings, Changes Outlook To Positive On I..
MT
2020CONVATEC  : Q3 Trading update for the three months ended 30 September 2020
PU
2020CONVATEC  : Trading update for the three months ended 30 September 2020 28 Octob..
PU
More news
Financials (USD)
Sales 2021 1 982 M - -
Net income 2021 139 M - -
Net Debt 2021 821 M - -
P/E ratio 2021 43,6x
Yield 2021 1,86%
Capitalization 5 770 M 5 769 M -
EV / Sales 2021 3,33x
EV / Sales 2022 3,13x
Nbr of Employees 9 914
Free-Float 79,6%
Chart CONVATEC GROUP PLC
Duration : Period :
ConvaTec Group Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CONVATEC GROUP PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 3,08 $
Last Close Price 2,88 $
Spread / Highest target 31,1%
Spread / Average Target 6,76%
Spread / Lowest Target -22,9%
EPS Revisions
Managers and Directors
NameTitle
Karim Sani Nasib Bitar Chief Executive Officer & Director
Frank M. Schulkes Chief Financial Officer & Director
John David Gibson McAdam Chairman
Robert Steele EVP-Quality, Clinical & Regulatory Affairs
Donal Balfe Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capitalization (M$)
CONVATEC GROUP PLC3.41%5 769
ABBOTT LABORATORIES13.57%220 290
MEDTRONIC PLC7.49%169 736
BECTON, DICKINSON AND COMPANY3.49%75 819
ALIGN TECHNOLOGY, INC.12.98%47 982
HOYA CORPORATION-3.89%46 093